Loading
A phase 1/2 trial of Ripretinib in advanced solid tumours, run by Deciphera Pharmaceuticals, LLC, now recruiting.
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies is a phase 1/2 interventional study registered as NCT05957367 by Deciphera Pharmaceuticals, LLC, with 94 participants planned, started 2023-09-28 and due to reach its primary completion in 2027-03. Interventions recorded: Inlexisertib and Ripretinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares DCC, Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Ripretinib, Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/